Table 1.
Baseline postoperative tumour and patient characteristics by receipt of chemotherapy.
| Variable | Category | Chemotherapy |
No chemotherapy |
Total |
|---|---|---|---|---|
| N = 376 | N = 1144 | N = 1520 | ||
| Participation level | Full | 304 (80.9%) | 816 (71.3%) | 1120 (73.7%) |
| Partial | 68 (18.1%) | 284 (24.8%) | 352 (23.2%) | |
| Consultee | 4 (1.1%) | 44 (3.8%) | 48 (3.2%) | |
| Main side | Right | 169 (44.9%) | 545 (47.6%) | 714 (47.0%) |
| Left | 207 (55.1%) | 599 (52.4%) | 806 (53.0%) | |
| Tumour size (mm) | n | 375 | 1143 | 1518 |
| Mean (SD) | 32.9 (20.7) | 29.0 (17.5) | 29.9 (18.4) | |
| Median (IQR) | 29.0 (21.0, 40.0) | 25.0 (18.0, 35.0) | 25.0 (18.2, 36.0) | |
| Min, Max | 0, 210 | 0, 155 | 0, 210 | |
| Tumour size (mm) | ≤20 | 93 (24.7%) | 399 (34.9%) | 492 (32.4%) |
| 21–50 | 233 (62.0%) | 644 (56.3%) | 877 (57.7%) | |
| >50 | 49 (13.0%) | 100 (8.7%) | 149 (9.8%) | |
| Unknown | 1 (0.3%) | 1 (0.1%) | 2 (0.1%) | |
| Grade | Grade I | 2 (0.5%) | 77 (6.7%) | 79 (5.2%) |
| Grade II | 122 (32.4%) | 447 (39.1%) | 569 (37.4%) | |
| Grade III | 247 (65.7%) | 617 (53.9%) | 864 (56.8%) | |
| Unknown | 5 (1.3%) | 3 (0.3%) | 8 (0.5%) | |
| Histology | Ductal NST | 270 (71.8%) | 813 (71.1%) | 1083 (71.2%) |
| Lobular carcinoma | 52 (13.8%) | 110 (9.6%) | 162 (10.7%) | |
| Tubular carcinoma | 0 (0.0%) | 5 (0.4%) | 5 (0.3%) | |
| Mucinous carcinoma | 1 (0.3%) | 13 (1.1%) | 14 (0.9%) | |
| Other | 29 (7.7%) | 97 (8.5%) | 126 (8.3%) | |
| Unknown | 24 (6.4%) | 106 (9.3%) | 130 (8.6%) | |
| ER positive? | No | 132 (35.1%) | 240 (21.0%) | 372 (24.5%) |
| Yes | 241 (64.1%) | 893 (78.1%) | 1134 (74.6%) | |
| Unknown | 3 (0.8%) | 11 (1.0%) | 14 (0.9%) | |
| HER2 status | Negative | 210 (55.9%) | 908 (79.4%) | 1118 (73.6%) |
| Inconclusive | 3 (0.8%) | 7 (0.6%) | 10 (0.7%) | |
| Positive | 159 (42.3%) | 173 (15.1%) | 332 (21.8%) | |
| Unknown | 4 (1.1%) | 56 (4.9%) | 60 (3.9%) | |
| Oncotype Dx test performed | No | 35 (9.3%) | 150 (13.1%) | 185 (12.2%) |
| Yes | 5 (1.3%) | 16 (1.4%) | 21 (1.4%) | |
| Not Applicable | 252 (67.0%) | 434 (37.9%) | 686 (45.1%) | |
| Unknown | 84 (22.3%) | 544 (47.6%) | 628 (41.3%) | |
| Breast surgery | Wide local excision (non wire localised) | 113 (30.1%) | 412 (36.0%) | 525 (34.5%) |
| Wire localised wide local excision | 43 (11.4%) | 150 (13.1%) | 193 (12.7%) | |
| Therapeutic mammoplasty/breast reshaping after WLE | 18 (4.8%) | 14 (1.2%) | 32 (2.1%) | |
| Mastectomy | 186 (49.5%) | 549 (48.0%) | 735 (48.4%) | |
| Mastectomy and reconstruction | 12 (3.2%) | 11 (1.0%) | 23 (1.5%) | |
| Other | 4 (1.1%) | 8 (0.7%) | 12 (0.8%) | |
| Axillary surgery | Axillary sample | 11 (2.9%) | 38 (3.3%) | 49 (3.2%) |
| Axillary clearance | 136 (36.2%) | 247 (21.6%) | 383 (25.2%) | |
| Sentinel lymph node biopsy | 200 (53.2%) | 725 (63.4%) | 925 (60.9%) | |
| Internal mammary node biopsy | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) | |
| No axillary surgery | 7 (1.9%) | 27 (2.4%) | 34 (2.2%) | |
| Unknown | 22 (5.9%) | 106 (9.3%) | 128 (8.4%) | |
| Nodal status | pN0-1mi | 175 (46.5%) | 508 (44.4%) | 683 (44.9%) |
| pN1 | 117 (31.1%) | 494 (43.2%) | 611 (40.2%) | |
| pN2 | 52 (13.8%) | 95 (8.3%) | 147 (9.7%) | |
| pN3 | 32 (8.5%) | 46 (4.0%) | 78 (5.1%) | |
| pNx | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) | |
| Nottingham Prognostic Index | n | 371 | 1139 | 1510 |
| Mean (SD) | 5.1 (1.0) | 4.7 (0.9) | 4.8 (1.0) | |
| Median (IQR) | 4.9 (4.4, 5.7) | 4.5 (4.3, 5.3) | 4.6 (4.3, 5.4) | |
| Min, Max | 2.4, 10.2 | 2.1, 8.1 | 2.1, 10.2 | |
| Age | n | 376 | 1144 | 1520 |
| Mean (SD) | 73.65 (3.33) | 77.97 (5.19) | 76.90 (5.14) | |
| Median (IQR) | 73.00 (71.00, 76.00) | 78.00 (74.00, 81.00) | 76.00 (72.00, 80.00) | |
| Min, Max | 69, 87 | 69, 95 | 69, 95 | |
| Charlson comorbidity index (no age) | n | 365 | 1103 | 1468 |
| Mean (SD) | 0.79 (1.08) | 1.11 (1.38) | 1.03 (1.32) | |
| Median (IQR) | 0.00 (0.00, 2.00) | 1.00 (0.00, 2.00) | 1.00 (0.00, 2.00) | |
| Min, Max | 0, 6 | 0, 9 | 0, 9 | |
| Charlson calculated probability | n | 365 | 1103 | 1468 |
| Mean (SD) | 0.56 (0.26) | 0.43 (0.29) | 0.46 (0.29) | |
| Median (IQR) | 0.77 (0.21, 0.77) | 0.53 (0.21, 0.77) | 0.53 (0.21, 0.77) | |
| Min, Max | 0, 0.77 | 0, 0.77 | 0, 0.77 | |
| Number of concurrent medications | n | 314 | 1021 | 1335 |
| Mean (SD) | 3.66 (2.51) | 4.30 (2.69) | 4.15 (2.66) | |
| Median (IQR) | 3.00 (2.00, 5.00) | 4.00 (2.00, 6.00) | 4.00 (2.00, 6.00) | |
| Min, Max | 0, 14 | 0, 18 | 0, 18 | |
| ADL category | No dependency | 303 (80.6%) | 760 (66.4%) | 1063 (69.9%) |
| Mild dependency | 33 (8.8%) | 146 (12.8%) | 179 (11.8%) | |
| Moderate/severe dependency | 16 (4.3%) | 136 (11.9%) | 152 (10.0%) | |
| Unknown | 24 (6.4%) | 102 (8.9%) | 126 (8.3%) | |
| IADL category | No dependency | 315 (83.8%) | 776 (67.8%) | 1091 (71.8%) |
| Mild dependency | 26 (6.9%) | 124 (10.8%) | 150 (9.9%) | |
| Moderate/severe dependency | 10 (2.7%) | 136 (11.9%) | 146 (9.6%) | |
| Unknown | 25 (6.6%) | 108 (9.4%) | 133 (8.7%) | |
| MMSE category | Normal function | 342 (91.0%) | 1004 (87.8%) | 1346 (88.6%) |
| Mild impairment | 28 (7.4%) | 111 (9.7%) | 139 (9.1%) | |
| Moderate impairment | 4 (1.1%) | 14 (1.2%) | 18 (1.2%) | |
| Severe | 2 (0.5%) | 15 (1.3%) | 17 (1.1%) | |
| APG SGA category | Low | 299 (79.5%) | 869 (76.0%) | 1168 (76.8%) |
| Moderate | 38 (10.1%) | 125 (10.9%) | 163 (10.7%) | |
| High | 4 (1.1%) | 19 (1.7%) | 23 (1.5%) | |
| Unknown | 35 (9.3%) | 131 (11.5%) | 166 (10.9%) | |
| ECOG performance status | Fully active | 296 (78.7%) | 740 (64.7%) | 1036 (68.2%) |
| Restricted in physically strenuous activity | 59 (15.7%) | 284 (24.8%) | 343 (22.6%) | |
| Ambulatory and capable of all self-care | 3 (0.8%) | 43 (3.8%) | 46 (3.0%) | |
| Capable of only limited self-care | 2 (0.5%) | 18 (1.6%) | 20 (1.3%) | |
| Unknown | 16 (4.3%) | 59 (5.2%) | 75 (4.9%) |
SD, standard deviation; IQR, interquartile range; NST, no special type; ADL, activities of daily living; IADL, instrumental activities of daily living; MMSE, Mini–Mental State Examination; APG SGA, Abridged Patient-Generated Subjective Global Assessment; ECOG, Eastern Cooperative Oncology Group.